The EDGE

What we know and mostly do not know about bronchiolitis obliterans syndrome

P J Martin and J W Chien

Bone Marrow Transplant 2012 47: 1-4; 10.1038/bmt.2011.38

Review

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

I Danylesko, A Shimoni and A Nagler

Bone Marrow Transplant 2012 47: 5-14; advance online publication, April 11, 2011; 10.1038/bmt.2011.88

Special Report

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

C Chabannon, D Pamphilon, C Vermylen, A Gratwohl, D Niederwieser, E McGrath, C Lamers, F Lanza, I Slaper-Cortenbach, A Madrigal and J Apperley

Bone Marrow Transplant 2012 47: 15-17; advance online publication, March 7, 2011; 10.1038/bmt.2011.32

Original Articles

STEM CELL PROCUREMENT

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

K W Douglas, A N Parker, P J Hayden, A Rahemtulla, A D'Addio, R M Lemoli, K Rao, M Maris, A Pagliuca, J Uberti, C Scheid, R Noppeney, G Cook, S W Bokhari, N Worel, G Mikala, T Masszi, R Taylor and J Treisman

Bone Marrow Transplant 2012 47: 18-23; advance online publication, February 28, 2011; 10.1038/bmt.2011.9

Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation

G Milone, M Poidomani, S Leotta, G Avola, M G Camuglia, A Privitera, C Consoli, S Mercurio, M A Romeo, A Di Marco, S Di Mercurio, A Spadaro, G A Palumbo and P Tedeschi

Bone Marrow Transplant 2012 47: 24-32; advance online publication, March 14, 2011; 10.1038/bmt.2011.33

CORD BLOOD STEM CELLS

Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients

T-H Jaing, I-J Hung, C-P Yang, S-H Chen, H-T Chung, P-K Tsay and Y-C Wen

Bone Marrow Transplant 2012 47: 33-39; advance online publication, March 7, 2011; 10.1038/bmt.2011.39

POST-TRANSPLANT EVENTS

Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders

T S Cole, I C Johnstone, M S Pearce, B Fulton, A J Cant, A R Gennery and M A Slatter

Bone Marrow Transplant 2012 47: 40-45; advance online publication, February 28, 2011; 10.1038/bmt.2011.26

ALLOGRAFTING

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

C Schmid, M Schleuning, J Tischer, E Holler, K-H Haude, J Braess, C Haferlach, H Baurmann, D Oruzio, J Hahn, K Spiekermann, G Schlimok, R Schwerdtfeger, T Buechner, W Hiddemann and H-J Kolb

Bone Marrow Transplant 2012 47: 46-53; advance online publication, February 28, 2011; 10.1038/bmt.2011.15

CsA 2-h concentration correlates best with area under the concentration–time curve after allo-SCT compared with trough CsA

D C M Kong, P Shuttleworth, M Bailey and A Grigg

Bone Marrow Transplant 2012 47: 54-59; advance online publication, February 14, 2011; 10.1038/bmt.2011.2

Prognostic impact of iron parameters in patients undergoing allo-SCT

G N Bazuave, A Buser, S Gerull, A Tichelli and M Stern

Bone Marrow Transplant 2012 47: 60-64; advance online publication, March 14, 2011; 10.1038/bmt.2011.13

Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine–melphalan conditioning for treatment of mature T-cell lymphomas

M Delioukina, J Zain, J M Palmer, N Tsai, S Thomas and S Forman

Bone Marrow Transplant 2012 47: 65-72; advance online publication, February 28, 2011; 10.1038/bmt.2011.16

G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT

Y-C Su, S-C Li, C-K Hsu, C-C Yu, T-J Lin, C-Y Lee and H-F Liao

Bone Marrow Transplant 2012 47: 73-81; advance online publication, February 28, 2011; 10.1038/bmt.2011.22

AUTOGRAFTING

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma

D G Stover, V K Reddy, Y Shyr, B N Savani and N Reddy

Bone Marrow Transplant 2012 47: 82-87; advance online publication, February 28, 2011; 10.1038/bmt.2011.29

MICROBIAL ISSUES

The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study

R E Protheroe, K E Kirkland, R M Pearce, K Kaminaris, A Bloor, M N Potter, S Nagra, M H Gilleece, I G McQuaker, G Jackson, G Cook and D I Marks

Bone Marrow Transplant 2012 47: 88-94; advance online publication, February 28, 2011; 10.1038/bmt.2011.12

PEDIATRIC TRANSPLANTS

Secondary solid tumors after allogeneic hematopoietic SCT in Japan

A Yokota, S Ozawa, T Masanori, H Akiyama, K Ohshima, Y Kanda, S Takahashi, T Mori, C Nakaseko, M Onoda, K Kishi, N Doki, N Aotsuka, H Kanamori, A Maruta, H Sakamaki and S Okamoto for the Kanto Study Group for Cell Therapy (KSGCT)

Bone Marrow Transplant 2012 47: 95-100; advance online publication, February 28, 2011; 10.1038/bmt.2011.23

GRAFT-VERSUS-HOST DISEASE

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT

A Dominietto, E Tedone, M Soracco, B Bruno, A M Raiola, M T Van Lint, S Geroldi, T Lamparelli, B Galano, F Gualandi, F Frassoni and A Bacigalupo

Bone Marrow Transplant 2012 47: 101-106; advance online publication, April 4, 2011; 10.1038/bmt.2011.28

Higher CD3⁺ and CD34⁺ cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia

J Gaziev, A Isgrò, M Marziali, N Daniele, C Gallucci, P Sodani, M D Simone, G Adorno, K Paciaroni, M Andreani, A Lanti, G Del Proposto, M Testi, G De Angelis, A Roveda, C Alfieri, F Saltarelli and G Lucarelli

Bone Marrow Transplant 2012 47: 107-114; advance online publication, February 14, 2011; 10.1038/bmt.2011.3

Tear physiology in dry eye associated with chronic GVHD

S Khanal and A Tomlinson

Bone Marrow Transplant 2012 47: 115-119; advance online publication, March 7, 2011; 10.1038/bmt.2011.36

The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis

P Chiusolo, S Bellesi, N Piccirillo, S Giammarco, S Marietti, D De Ritis, E Metafuni, M Stignani, O R Baricordi, S Sica, G Leone and R Rizzo

Bone Marrow Transplant 2012 47: 120-124; advance online publication, March 14, 2011; 10.1038/bmt.2011.40

Prognostic value of response after upfront therapy for acute GVHD

R M Saliba, D R Couriel, S Giralt, G Rondon, G-J Okoroji, A Rashid, R E Champlin and A M Alousi

Bone Marrow Transplant 2012 47: 125-131; advance online publication, March 7, 2011; 10.1038/bmt.2011.41

Letters to the Editor

A case of membranous nephropathy associated with chronic GVHD successfully treated with rituximab

E Iguchi, T Minakata and M Tsudo

Bone Marrow Transplant 2012 47: 132-134; advance online publication, February 14, 2011; 10.1038/bmt.2011.4

Intensive chemotherapy for a relapsed ALL patient who received living-donor lobar lung transplantation

K Ishiyama, H Okumura, H Yamazaki, Y Kondo, Y Waseda, T Kotani, A Takami and S Nakao

Bone Marrow Transplant 2012 47: 135-136; advance online publication, February 7, 2011; 10.1038/bmt.2011.5

Molecular remission of FLT3-ITD⁺ positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib

W H Krüger, C Hirt, T Kiefer, T Neumann, C Busemann and G Dölken

Bone Marrow Transplant 2012 47: 137-138; advance online publication, March 21, 2011; 10.1038/bmt.2011.7

Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD

T Osumi, M Miharu, R Tanaka, W Du, T Takahashi and H Shimada

Bone Marrow Transplant 2012 47: 139-140; advance online publication, February 21, 2011; 10.1038/bmt.2011.10

Encouraging results of preserving ovarian function after allo-HSCT with RIC

M Shimizu, A Sawada, K Yamada, O Kondo, M Koyama-Sato, S Shimizu, H Komura, M Yasui, M Inoue and K Kawa

Bone Marrow Transplant 2012 47: 141-142; advance online publication, March 14, 2011; 10.1038/bmt.2011.14

Circulating CD34⁺ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT

H Alchalby, M Lioznov, U Fritzsche-Friedland, A Badbaran, T Zabelina, U Bacher, T Stübig, F A Ayuk, A R Zander and N Kröger

Bone Marrow Transplant 2012 47: 143-145; advance online publication, February 28, 2011; 10.1038/bmt.2011.17

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

F T Awan, S Osman, S T Kochuparambil, L Gibson, S C Remick, J Abraham, M Craig, A Jillella and M Hamadani

Bone Marrow Transplant 2012 47: 146-148; advance online publication, February 28, 2011; 10.1038/bmt.2011.18

Oral cavity care in patients after high-dose chemotherapy and stem cell transplantation: The East Forum EBMT Nurses Group standard of care

E Bystricka, R Ghelase, I K S Gorican, E Mazur and S Vokurka on behalf of the East Forum EBMT Nurses Group

Bone Marrow Transplant 2012 47: 149-150; advance online publication, February 28, 2011; 10.1038/bmt.2011.19

Serum (1 → 3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement

U Duffner, A Abdel-Mageed, K Dahl, G Fogg and J Hester

Bone Marrow Transplant 2012 47: 151-152; advance online publication, February 28, 2011; 10.1038/bmt.2011.24

Severe pruritus and hypothermia as the primary manifestations of Human Herpes Virus-6 encephalitis after pediatric cord blood transplantation

M Hudspeth, Evangeline Brown, D Ragucci, T Dixon and R Turner

Bone Marrow Transplant 2012 47: 153-154; advance online publication, February 28, 2011; 10.1038/bmt.2011.25

Carcinomatosis lymphangitis and pleurisy after allo-SCT in two patients with secondary leukemia after breast cancer

E Chalayer, E Tavernier-Tardy, G Clavreul, J-O Bay and J Cornillon

Bone Marrow Transplant 2012 47: 155-156; advance online publication, March 7, 2011; 10.1038/bmt.2011.30

Allogeneic hematopoietic stem cell collection from a donor with end-stage renal disease

I Ahmad, T Kiss, S Lachance, J Roy and S Cohen

Bone Marrow Transplant 2012 47: 157-158; advance online publication, February 28, 2011; 10.1038/bmt.2011.31

Successful allo-HSCT with a minimal myeloablative conditioning regimen in an adult patient with Fanconi’s anemia

K Maekawa, M Yoshimitsu, H Fujiwara, K Matsushita, H Kawada, H Hamada, S Suzuki, K Uozumi, M Ohtsuka, S Hanada, M Yabe, H Yabe and N Arima

Bone Marrow Transplant 2012 47: 159-160; advance online publication, March 7, 2011; 10.1038/bmt.2011.34